HRP20040261A2 - Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline - Google Patents

Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline Download PDF

Info

Publication number
HRP20040261A2
HRP20040261A2 HR20040261A HRP20040261A HRP20040261A2 HR P20040261 A2 HRP20040261 A2 HR P20040261A2 HR 20040261 A HR20040261 A HR 20040261A HR P20040261 A HRP20040261 A HR P20040261A HR P20040261 A2 HRP20040261 A2 HR P20040261A2
Authority
HR
Croatia
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
dimethoxy
pyridyl
quinazoline
Prior art date
Application number
HR20040261A
Other languages
English (en)
Croatian (hr)
Inventor
John Douglas Davis
Michael John Humphrey
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP20040261A2 publication Critical patent/HRP20040261A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20040261A 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline HRP20040261A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations
PCT/IB2002/004040 WO2003032956A1 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number Publication Date
HRP20040261A2 true HRP20040261A2 (en) 2004-08-31

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040261A HRP20040261A2 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline

Country Status (33)

Country Link
EP (1) EP1434570B8 (de)
JP (1) JP4131471B2 (de)
KR (1) KR20050032510A (de)
CN (1) CN1568180A (de)
AP (1) AP2004003001A0 (de)
AR (1) AR036782A1 (de)
AT (1) ATE303135T1 (de)
BR (1) BR0213196A (de)
CA (1) CA2461168A1 (de)
CO (1) CO5560534A2 (de)
DE (1) DE60205925T2 (de)
DK (1) DK1434570T3 (de)
DO (1) DOP2002000464A (de)
EA (1) EA006168B1 (de)
ES (1) ES2246017T3 (de)
GB (1) GB0124455D0 (de)
GT (1) GT200200184A (de)
HR (1) HRP20040261A2 (de)
HU (1) HUP0600064A3 (de)
IL (1) IL160969A0 (de)
IS (1) IS7179A (de)
MA (1) MA27075A1 (de)
MX (1) MXPA04003293A (de)
NO (1) NO20041520L (de)
OA (1) OA12709A (de)
PA (1) PA8556001A1 (de)
PE (1) PE20030551A1 (de)
PL (1) PL369666A1 (de)
PY (1) PY0223360A (de)
SV (1) SV2004001279A (de)
UY (1) UY27477A1 (de)
WO (1) WO2003032956A1 (de)
ZA (1) ZA200401976B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466986B1 (de) * 1990-07-02 1994-04-27 Bend Research, Inc. Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
WO2001064672A1 (en) * 2000-03-03 2001-09-07 Pfizer Limited 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs

Also Published As

Publication number Publication date
AP2004003001A0 (en) 2004-03-31
PE20030551A1 (es) 2003-06-26
OA12709A (en) 2006-06-26
EA200400431A1 (ru) 2004-08-26
EA006168B1 (ru) 2005-10-27
ATE303135T1 (de) 2005-09-15
CA2461168A1 (en) 2003-04-24
AR036782A1 (es) 2004-10-06
IS7179A (is) 2004-03-11
NO20041520L (no) 2004-04-05
ES2246017T3 (es) 2006-02-01
HUP0600064A3 (en) 2007-02-28
HUP0600064A2 (en) 2006-06-28
MA27075A1 (fr) 2004-12-20
GT200200184A (es) 2003-05-23
WO2003032956A1 (en) 2003-04-24
PL369666A1 (en) 2005-05-02
UY27477A1 (es) 2003-05-30
EP1434570B1 (de) 2005-08-31
MXPA04003293A (es) 2004-07-23
BR0213196A (pt) 2004-08-31
IL160969A0 (en) 2004-08-31
DK1434570T3 (da) 2005-11-07
GB0124455D0 (en) 2001-12-05
JP2005507909A (ja) 2005-03-24
PY0223360A (es) 2004-04-01
KR20050032510A (ko) 2005-04-07
DE60205925T2 (de) 2006-06-08
CO5560534A2 (es) 2005-09-30
ZA200401976B (en) 2004-07-12
DOP2002000464A (es) 2003-04-15
EP1434570A1 (de) 2004-07-07
JP4131471B2 (ja) 2008-08-13
EP1434570B8 (de) 2005-10-26
SV2004001279A (es) 2004-02-19
CN1568180A (zh) 2005-01-19
PA8556001A1 (es) 2003-07-28
DE60205925D1 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
US11452689B2 (en) Taste-masked pharmaceutical compositions
US10471017B2 (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
RU2428176C2 (ru) Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
CN100402021C (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
AU2005307052B2 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
RU2325163C2 (ru) Композиции с пролонгированным высвобождением, включающие ламотригин
US7163696B2 (en) Pharmaceutical formulations
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
WO2009114773A2 (en) Modified release formulations of anti-irritability drugs
US20030039699A1 (en) Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
EP1589950A1 (de) Verfahren zur herstellung pharmazeutischer darreichungsformen mit aktiven kompressionsbestandteilen
WO2001080824A2 (en) Dual mechanism timed release dosage forms for low dose drugs
KR20080037680A (ko) 1-(4-클로로아닐리노)-4-(4-피리딜메틸)프탈라진 및 ph조절제를 포함하는 고체 제약학적 조성물
US20070082051A1 (en) Modified Release Formulations of Antihypertensive Drugs
EP1434570B1 (de) Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisochinol-2-yl)-5-(2-pyridyl)chinazolin
JP2004339072A (ja) 優れた安定性を有するプラバスタチンナトリウム固形製剤
AU2002341260A1 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
MXPA01002821A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
HK1163502A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
HK1109337B (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn